Aptevo Therapeutics Inc. APVO
We take great care to ensure that the data presented and summarized in this overview for Aptevo Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APVO
Top Purchases
Top Sells
About APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Transactions at APVO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 08
2024
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
213
+21.01%
|
-
|
Aug 08
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
158
+21.53%
|
-
|
Aug 08
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
314
+11.7%
|
-
|
Jun 02
2024
|
John Niederhuber |
BUY
Exercise of conversion of derivative security
|
Direct |
81
+27.18%
|
-
|
Jun 02
2024
|
Grady Grant Iii |
BUY
Exercise of conversion of derivative security
|
Direct |
81
+29.03%
|
-
|
Jun 02
2024
|
Barbara Lopez Kunz |
BUY
Exercise of conversion of derivative security
|
Direct |
81
+29.03%
|
-
|
Jun 02
2024
|
Daniel Abdun Nabi |
BUY
Exercise of conversion of derivative security
|
Direct |
81
+22.63%
|
-
|
Jun 02
2024
|
Zsolt Harsanyi |
BUY
Exercise of conversion of derivative security
|
Direct |
81
+22.44%
|
-
|
Jun 01
2024
|
John Niederhuber |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+4.9%
|
-
|
Jun 01
2024
|
Grady Grant Iii |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+5.65%
|
-
|
Jun 01
2024
|
Barbara Lopez Kunz |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+5.65%
|
-
|
Jun 01
2024
|
Daniel Abdun Nabi |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+3.45%
|
-
|
Jun 01
2024
|
Zsolt Harsanyi |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+3.4%
|
-
|
May 31
2024
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
42
+6.67%
|
-
|
Mar 04
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,584
+7.92%
|
-
|
Mar 03
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+8.91%
|
-
|
Mar 03
2024
|
Marvin L White President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,584
+12.44%
|
-
|
Mar 03
2024
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+13.23%
|
-
|
Mar 02
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+13.98%
|
-
|
Mar 02
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+17.89%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 52.8K shares |
---|